Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GFM-DA is a topical cosmetic gel developed by Cantabria Labs Difa Cooper for the treatment of hair loss conditions such as androgenic alopecia and telogen effluvium. It contains a combination of biotechnologically derived oligopeptides that mimic the biological activity of endogenous growth factors, including insulin-like growth factor 1 (IGF-1), keratinocyte growth factor (KGF), fibroblast growth factor 7 (FGF-7), and vascular endothelial growth factor (VEGF). These peptides regulate the hair growth cycle and protect hair follicles from protease-mediated destruction. The formulation also includes caffeine to enhance scalp microcirculation, taurine for hair protection, and a lactoferrin-based iron-chelating complex (Trikelan) in a hyaluronic acid base. It is typically used as an adjuvant to standard pharmacological treatments like minoxidil or finasteride.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GFM-DA.